Abu zahran

ASCO this year has 5,000+ abstracts. But ~24 will actually change practice. Here is that map. Data-grid is the shortest path through ASCO 2026: 12 disease areas, 24 critical readouts, 5 plenaries, and 2 (confirmed) misses already on the board. Few things jump out immediately: ▪️Daraxonrasib gets the headline (13.2 vs 6.7 mo) ▫️Sarcoma gets a plenary as public science funds P3 that pharma would not. ▫️Lung cancer remains crowded: RET adjuvant, bispecific OS, post-osimertinib, next-gen EGFR. ▫️Breast cancer reminds us that not every big swing lands By next week, only a handful of these cells will become new standards of care. This is your cheat sheet to keep that score. - - - - - Source: @asco · @OncLive · @CancerNetwrk · via @Jori_health - - - - -

@UTDIMole Hargreaves

Guess the missing player 99% of football fans will fail this.

@LegacySiu @CFCHaven Guiseppe Rossi

@CFCHaven Could be easy for man utd fans

Name an Italian that has played for Manchester United HARD

@LegacySiu Guiseppe Rossi

@UTDMael Case

Guess the player💨💨 Level=pro

@LegacySiu Fulham

Name a football club without letter "E" You can’t

@_onlyscott Fulham

@TifeRMFC Michael Owen

Despite the many real & painful challenges that remain, 2025 was another year with remarkable advances in #PancreaticCancer research & clinical care. I summarized my list of top ten peer reviewed publications. Apologies to the many deserving papers & authors not here, please add!

@Mishi_2210 986

Tell me the number that is greater then this 99.9% will fail

The "Wild West" of post-CDK4/6i HR+/HER2- mBC is finally getting a map. 🗺️ We are moving from empiric sequencing to precision flowcharts. 🔑 Key Pivot: Your 2L choice now depends entirely on ESR1 and PI3K/AKT/PTEN status. Here is the modern treatment algorithm ⬇️ #SABCS25 #bcsm @OncoAlert

Doublet vs Triplet in mHSPC: Fast Takeaways 🔍 #GlobalForum25 #PROSCA25 🧬 ADT + ARPI = SOC Intensify only when biology or volume demands it. 💥 Doublet enough 😊 Metachronous low volume 😊 Elderly low volume 😊 Low risk biology 👉 ADT + ARPI 🔥 Biology driven intensification 🚨 TP53 or RB1 loss 🚨 PTEN loss 🚨 BRCA or HRR mutations 👉 Add docetaxel 💜 Clear Triplet candidates ⚡ De novo high volume ⚡ AR independent or high proliferative biology 👉 Triplet gives strongest OS effect 🌫️ Avoid intensification 🧓 Frail or comorbid 👉 ADT alone or ARPI if tolerated New Triplets 🆕 🟦 AMPLITUDE: Niraparib 🟩 CAPItello: Capivasertib 🟧 PSMAddition: LuPSMA Different biology, different triplet. #OncoTwitter #MedTwitter #ProstateCancer #mHSPC @oncoalert @asco @myesmo @esmo_open @mirrorsmed

@RobertaFresque2 116

🤔

🔥 New KRAS G12C combo making noise in NSCLC? Olomorasib + Pembrolizumab hits 90% ORR in PD-L1 ≥50% first-line patients 🤯 (Phase 1b – LOXO-RAS-20001, JTO) 🧬 Why this matters? Past KRAS G12C + IO combos = hepatotoxicity nightmares 😬 Olomorasib is next-gen, ultra-selective → better tolerability + deeper target occupancy. 📊 Key Results 1️⃣ Overall (n=91) • ORR: 57% • DCR: 86% • Median DOR: 17.2 mo • Median PFS: 11.8 mo 2️⃣ First-line (n=46) • ORR: 73.9% • 12-mo PFS: 66.7% • Median DOR/PFS: NR 3️⃣ PD-L1 ≥50% first-line (n=20) • 🔥 ORR: 90% • Responses across PD-L1 50–100% 🛡️ Safety • Grade ≥3 TRAEs: 33% • Common: diarrhea (34%), ↑ALT (25%), ↑AST (23%) • No grade 5 events • LFT rises = manageable + reversible • Dual discontinuation: 6.5% 🧬 Biomarkers • Responses despite STK11, KEAP1, SMARCA4 • ctDNA drop ≥90% in 77% • KRAS clearance in 68% 🔍 Takeaway Olomorasib + pembrolizumab shows strong activity + better tolerability than earlier G12C+IO combos. Especially exciting for PD-L1-high first-line KRAS G12C NSCLC. 👉 Phase 3: SUNRAY-01 & SUNRAY-02 📖 doi link in comment below #OncoTwitter #MedTwitter #LCSM #NSCLC #KRAS #Immunotherapy #TargetedTherapy @myESMO @esmo_open @OncoAlert @IASLC @ASCO @JournalThorOnc

@rioferdy5 A

Debate…. A) Mane, Firmino, Salah B) Rooney, Ronaldo, Tevez C) Pires, Henry, Berkamp Who u going for?

DLBCL treatment has gotten more complicated Back in my day it was RCHOP if relapse salvage and ASCT

@NicoGagelmann IPA with halo sign

Here is a CT of a patient on broad spectrum antibiotics but persistent fever and high CRP. Diagnosis?

How I manage MGUS in one Figure 👇

💊 PPIs in Cancer Care - Protective or Problematic? They shield the gut… but might blunt our drugs. ⚖️ 🎯 Why this matters in oncology? PPIs are commonly co-prescribed with: 🧪 Platinum chemo / steroids / NSAIDs 🩸 Antiplatelets or DOACs 💊 TKIs needing gastric acidity (erlotinib, pazopanib, capmatinib) ⚠️ Potential harms (esp. long-term): • 🦠 C. difficile infection ↑ (~1.7×) • 💧 CKD ↑ (HR ~1.3) • 🦴 Fractures ↑ (RR ~1.3) • 🧫 ↓ Mg²⁺, B12, Fe • 🧠 Possible ↓ ICI efficacy via gut microbiome alteration 🩺 PPI stewardship in cancer patients ✅ Confirm a clear GI indication ✅ Review every 8–12 weeks ✅ Step-down / switch to H2RA if mild reflux ✅ Educate on rebound acid hypersecretion 💡 Takeaway: “Treat PPIs like antibiotics - essential when needed, risky when indefinite.” 📘 Andrawes et al., Medicina 2025 🔗doi.org/10.3390/medici… #OncoTwitter #MedTwitter #DrugSafety #PPIs #Immunotherapy #GItoxicity @OncoAlert @ESMO_Open @myESMO @ASCO @medicina_mdpi

Low-dose Nivolumab and Lenalidomide in Relapsed/Refractory Hodgkin Lym... sciencedirect.com/science/articl…. @MathewsVikram @udaypkulkarni @drdatari